These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29184422)

  • 1. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China.
    Li Z; Chen ZW; Li H; Ren H; Hu P
    Infect Drug Resist; 2017; 10():377-392. PubMed ID: 29184422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors.
    Jiang X; Lv X; Chang L; Yan Y; Ji H; Sun H; Guo F; Rodgers MA; Yin P; Wang L
    Antiviral Res; 2020 Sep; 181():104871. PubMed ID: 32717286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational analysis of naturally occurring resistance-associated substitutions in genes
    Wu R; Geng D; Chi X; Wang X; Gao X; Xu H; Shi Y; Guan Y; Wang Y; Jin J; Ding Y; Niu J
    Infect Drug Resist; 2019; 12():2987-3015. PubMed ID: 31571951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.
    Liu Z; Mao X; Yu K; Suo C; Jin L; Zhang T; Chen X
    J Viral Hepat; 2020 Jun; 27(6):585-592. PubMed ID: 32049405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection.
    Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X
    Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
    Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
    Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting.
    Chen H; Liu J; Kang Q; Luo H; Tan N; Pan J; Yang Y; Yu M; Liu D; Xi H; Han Y; Cheng R; Yu Y; Xu X
    Infect Drug Resist; 2022; 15():3373-3380. PubMed ID: 35789797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection.
    Rahimi P; Sharafi H; Bahramali G; SajadianFard F; Asadi NS; Alavian SM; Iranpur Mobarakeh V; Moravej SZ
    Front Microbiol; 2020; 11():617375. PubMed ID: 33584581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
    Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
    Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
    Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F;
    JHEP Rep; 2022 May; 4(5):100462. PubMed ID: 35434589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C.
    Kyuregyan KK; Kichatova VS; Karlsen AA; Isaeva OV; Solonin SA; Petkov S; Nielsen M; Isaguliants MG; Mikhailov MI
    Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32272736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
    Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
    J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
    Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
    Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus.
    Tavares RCF; de Castro Amaral Feldner AC; Pinho JRR; de Mello Malta F; Carvalho-Filho RJ; Santana RAF; de Castro VFD; Dastoli GTF; Lima JC; Ferraz MLCG
    Infect Drug Resist; 2018; 11():1993-2000. PubMed ID: 30464541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
    Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.
    Mushtaq S; Hashmi AH; Khan A; Asad Raza Kazmi SM; Manzoor S
    Front Pharmacol; 2022; 13():894460. PubMed ID: 35571102
    [No Abstract]   [Full Text] [Related]  

  • 19. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.
    Li Z; Zhang Y; Liu Y; Shao X; Luo Q; Cai Q; Zhao Z
    Medicine (Baltimore); 2017 May; 96(19):e6830. PubMed ID: 28489763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.